----
Current ValuationThe current P/E ratio is -14.23, within the reasonable range, cheaper than 79.2% of the time in the past 5 years, and the industry ranks 51/74, the industry Median --.
-14.23xP/E
$1.39Stock price
$-0.10Earnings per share
-14.23xP/E
Stock price$1.39Earnings per share$-0.10
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -5.53x
- Typical range
- -15.01x–-3.90x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
07142128
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GHUSGuardant Health | -49.82x | 2.99% | $22.59B |
HIMSUSHims & Hers Health | -48.53x | 209.86% | $6.89B |
RDNTUSRadnet | -255.70x | 128.00% | $5.40B |
NEOUSNeogenomics | -39.55x | 64.43% | $2.05B |
WGSUSGeneDx | -19.22x | 359.59% | $2.04B |
AGLUSagilon health | -6.20x | 92.48% | $1.44B |
INNVUSInnovage | -491.05x | 2,301.70% | $1.25B |
OPKUSOpko Health | -14.23x | 25.99% | $1.04B |
LMRIUSLumexa Imaging | -36.69x | 145.51% | $1.02B |
CSTLUSCastle Biosciences | -51.93x | 52.61% | $1.01B |
FLGTUSFulgent Genetics | -6.71x | 42.64% | $565.99M |
GMRSUSGMR Solutions | -7.21x | 91.45% | $545.08M |
PREUSPrenetics Global | -8.20x | 16.63% | $385.21M |
BDSXUSBiodesix | -10.04x | 42.77% | $278.76M |
GAMGUSGlobal Asset Management Group, Inc. | -375.03x | -- | $211.68M |
NAKAUSNakamoto | -0.40x | 102.50% | $167.14M |
AIRSUSAirSculpt Tech | -11.18x | 33.33% | $131.21M |
CORBFUSGlobal Cord Blood Corporation | -- | -- | $127.35M |
PARKUSPark Dental Partners | -28.17x | -- | $99.58M |
EUDAUSEuda Health | -24.12x | 208.11% | $57.01M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
